Develops and commercializes specialized pharmaceutical products. Focuses on the ophthalmic domain, addressing eye-related conditions. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 34% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $49.7M a year. A small number, but proof the product has real buyers.
A loss of $51.7M against $49.7M in annual sales.
The stock sits at $0.0000. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 8.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.